Aug. 11 at 3:26 PM
$RGNT Bull Case 🐂
• Pivotal U.S. FDA trial 50%+ enrolled/treated
• Management targeting 80-patient enrollment completion in Q3 2026
• GelrinC already has CE Mark approval in Europe
• Preparing for European commercial launch
• Regional distributor engagement underway
• European surgeon training / Centers of Excellence strategy
• New manufacturing process improves production yield by roughly 5×
• Japanese patent allowance strengthens global IP
• ~
$13M micro-cap + only a few million shares estimated float = potential for extreme volatility on volume
• Multiple clinical + commercial catalysts ahead
• Stock has already demonstrated how violently it can reprice when a major catalyst hits
Thesis: depressed valuation + tiny float + Q3 enrollment catalyst + European commercialization = asymmetric speculative setup.
Watching for enrollment update / 80-of-80 + European commercial execution + volume.
